NxStage Medical

• Excellent Science + Unmet Need Equal Great Returns

  By Streetwise Reports - May 21, 2012 | Tickers: CRIS, GHDX, ISIS, MAKO, NXTM

  By George S. Mack, The Life Sciences Report

  Short-term gains come with pipeline products in mid-stage development.

  It is satisfying on those rare occasions when I get a straight answer to my first question in an interview for The Life Sciences Report. "Our theme is to focus on the markets with the most profit potential," answers Chief Investment Strategist Alex Daley of Casey's Extraordinary Technology. Daley has had some more »